Research programme: conjugated glucocorticoids - Manzanita Pharmaceuticals
Latest Information Update: 28 May 2022
At a glance
- Originator Manzanita Pharmaceuticals
- Class Analgesics; Drug conjugates; Glucocorticoids; Nerve growth factors
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Pain in USA (SC, Injection)
- 04 Apr 2018 Manzanita Pharmaceuticals has patent protection for intracellular delivery system to nerve cells in USA and Australia (Manzanita Pharmaceuticals website, April 2018)
- 04 Apr 2018 Pharmacodynamics data from a preclinical trial in Pain released by Manzanita Pharmaceuticals before April 2018(Manzanita Pharmaceuticals website, April 2018)